2026 New Year’s Greetings from the CEO

Core Insights - MediciNova, Inc. has navigated a challenging 2025 marked by global uncertainty, achieving significant milestones including the completion of patient enrollment in three clinical trials and launching a large-scale Expanded Access Program for ALS [1] Clinical Development Highlights - MN-001 (tipelukast) Phase 2 trial for hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), and Type 2 diabetes (T2DM) completed enrollment in November 2025, with top-line data expected in summer 2026 [3] - The COMBAT-ALS Study Phase 2b/3 trial for ALS completed enrollment in September 2025, with top-line results anticipated by year-end 2026 [7] - The Expanded Access Program for ALS, initiated in March 2025 with a $22 million NIH grant, has 12 active U.S. sites and 87 patients enrolled as of December 15, 2025 [7] - The OXTOX Study Phase 2b trial for chemotherapy-induced peripheral neuropathy in metastatic colon cancer completed enrollment in December 2025, with results timing yet to be determined [7] Company Overview - MediciNova is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases, with a strong pipeline based on MN-166 (ibudilast) and MN-001 (tipelukast) [5] - MN-166 is currently in Phase 3 for ALS and degenerative cervical myelopathy, and is Phase 3-ready for progressive multiple sclerosis [5]